Výsledky vyhledávání - "Luca Perjesi"

Akademický článek

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

Autor: Zsuzsanna Kahan, Daniela Grecea, Martin Smakal, Sergei Tjulandin, Igor Bondarenko, Luca Perjesi, Andras Illes, Karoly Horvat-Karajz, Ildiko Aradi

Publikováno v: BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)

Abstract Background Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia. RGB-02 (Gedeon Richter) is a proposed biosimilar to pegylated G-CSF (Neulasta�

Externí odkaz: https://doaj.org/article/b249d2754cfd438da7b013d32c4d7e50

Zobrazit plný text záznamu

Plný text ve formátu HTML

Abstract PD14-08: Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients

Autor: Anne C Armstrong, Steve Chan, Hans Wildiers, Frederik Marmé, Carolina P. Schröder, Jens Huober, Chrystelle Brignone, Eveline De Cuypere, Peter Vuylsteke, Jill Wagemans, Christian Mueller, Florence Dalenc, Frédéric Triebel, Jean-Philippe Jacquin, Luc Dirix, Sherko Kümmel, Zsuzsanna Papai, Luca Perjesi, Etienne Brain

Publikováno v: Cancer Research. 81:PD14-08

Background:Eftilagimod alpha (efti, IMP321),a soluble LAG-3 protein (LAG-3Ig) that binds to a subset of MHC class II molecules, mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. AIPAC (Active Immunotherapy PAClitaxe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c1e1c31f8b3abf55e3ceb4577f99733
https://doi.org/10.1158/1538-7445.sabcs20-pd14-08

Zobrazit plný text záznamu

Autor: Igor Bondarenko, Zsuzsanna Kahán, Martin Smakal, Karoly Horvat-Karajz, Andras Illes, Daniela Grecea, Sergei Tjulandin, Luca Perjesi, Ildiko Aradi

Publikováno v: BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)

Background Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia. RGB-02 (Gedeon Richter) is a proposed biosimilar to pegylated G-CSF (Neulasta®, Amgen)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6078b81798e3bd7c30b1b84933184cc
http://europepmc.org/articles/PMC6364429

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání